nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.06.2007 | Original Article

Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer

verfasst von: Koji Oba, Satoshi Teramukai, Michiya Kobayashi, Takanori Matsui, Yasuhiro Kodera, Junichi Sakamoto

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Non-specific immunopotentiators, such as polysaccharide K (PSK), also known as OK-432, induce anti-tumor effects via immunological responses. The efficacy of combination immunochemotherapy using these immunopotentiators has been examined by multiple previous studies. The survival benefits of immunochemotherapy for patients with curative resections of gastric cancers are not widely accepted. To clarify this issue, we performed a meta-analysis to evaluate the effect of immunochemotherapy on survival in patients with curative resections of gastric cancer. For this study, we compared the results of chemotherapy and immunotherapy using the biological response modifier PSK as an immunopotentiator. The meta-analysis included 8,009 patients from eight randomized controlled trials after central randomization. The overall hazard ratio for eligible patients was 0.88 (95% confidence interval, 0.79–0.98; P = 0.018) with no significant heterogeneity [χ ²(8) for heterogeneity = 11.7; P = 0.16]. The results of this meta-analysis suggest that adjuvant immunochemotherapy with PSK improves the survival of patients after curative gastric cancer resection.

Ferlay J, Bray F, Pisani P et al (2004) GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. IARC, Lyon

Sastre J, García-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12:204–213PubMed

Kobayashi H, Matsunaga K, Oguchi Y (1995) Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev 4:275–281PubMed

Ohno R, Yamada K, Masaoka T et al (1984) A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 18:149–154PubMedCrossRef

Sakamoto J, Morita S, Oba K et al (2006) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55:404–411PubMedCrossRef

Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343:1122–1126PubMedCrossRef

Nakajima T, Inokuchi K, Hattori T et al (1989) Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer—five-year survival rate (in Japanese). Gan To Kagaku Ryoho 16:799–806PubMed

Kim R, Yoshida K, Toge T (2002) Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma. Anticancer Res 22:283–289PubMed

Ikuzawa M, Matsunaga K, Nishiyama S et al (1988) Fate and distribution of an antitumor protein-bound polysaccharide PSK (Krestin). Int J Immunopharmacol 10:415–423PubMedCrossRef

10.

Higgins JPT, Green S (eds) (2005) Assessment study quality. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]; Section 6. The Cochrane Library, Issue 3. Wiley, Chichester, UK

11.

Parmar MB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834PubMedCrossRef

12.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef

13.

Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N (1988) Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 18:681–686

14.

Kondo T, Ichihashi H, Nakazato H, Ogawa N (1989) Result of adjuvant immunochemotherapy on 8 year survival using Krestin and Futraful for gastric cancer patients who underwent radical gastrectomy—a randomized controlled trial by cooperative study group (in Japanese). Biotherapy 3:655–664

15.

Kondo T, Sakamoto J, Nakazato H (1991) Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection. Biotherapy 3:287–295PubMedCrossRef

16.

Ogawa M, Kako H, Kitano T et al (1994) Cooperative study of adjuvant immunochemotherapy using HUFU (Mifurol^®) for gastric cancer patients who underwent curative resection (in Japanese). Rinsyo To Kenkyu 71:201–206

17.

18.

Ochiai T, Sato H, Sato H et al (1983) Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients. Cancer Res 43:3001–3007PubMed

19.

Fujimoto S, Furue H, Kimura T et al (1984) Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer—a randomized controlled trial. Jpn J Surg 14:286–292PubMedCrossRef

20.

Kanabe S, Tamakuma S, Mimura K et al (1985) Comparison of immunochemotherapy and chemotherapy of stage IV gastric carcinoma (in Japanese). Gan No Rinsho 31:1805–1809PubMed

21.

Sato S (1989) Study of validation of post-operative adjuvant chemotherapy following curative resection of stage II, III gastric cancer (in Japanese). Tokyo Ika Daigaku Zasshi 47:297–308

22.

Nio Y, Tobe T (1989) Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer (in Japanese). Nippon Geka Gakkai Zasshi 90:1436–1438PubMed

23.

Imaizumi M, Kondo T, Kamei H, Ichihashi H (1990) Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo’s group) (in Japanese). Gan to Kagaku Ryoho 17:2397–2403PubMed

24.

Fujimoto S, Furue H, Kimura T et al (1991) Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: a randomised controlled study. Eur J Cancer 27:1114–1118PubMedCrossRef

25.

Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M (1992) Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer 65:413–416PubMed

26.

Imaizumi M, Kondo T, Kamei H (1994) Cooperative study of postoperative long-term adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (second trial) (in Japanese). Gan No Rinsho 40:1243–1250

27.

Tanaka N, Aichi A, Nagata H et al (1995) Preoperative intra tumor biological response modifier injection therapy for patients with stomach neoplasm (in Japanese). Nihon Rinsho Meneki Gakkai Kaishi 18:626PubMed

28.

Osawa S, Shiroto H, Kondo Y, et al (1996) Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer (in Japanese). Gan To Kagaku Ryoho 23:327–331PubMed

29.

Imaizumi M, Kondo T, Kamei H, Ichihashi H (1984) Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (in Japanese). Gan to Kagaku Ryoho 11:60–68PubMed

30.

Nakajima T, Inokuchi K, Hattori T, et al (1985) A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer (in Japanese). Gan To Kagaku Ryoho 12:1850–1863PubMed

31.

Tamada R, Inokuchi K, Hattori T et al (1987) A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer (II) (in Japanese). Gan to Kagaku Ryoho 14:716–722PubMed

32.

Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N (1987) Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for curatively resected cases of gastric cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, Orlando, pp 515–524

33.

Ichihashi H, Kondo T, Nakazato H (1987) Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer—7-year survival—Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group (in Japanese). Gan to Kagaku Ryoho 14:2758–2766PubMed

34.

Nakazato H, Koike A, Ichihashi H, Saji S, Danno M, Ogawa N (1989) An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)—a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer (in Japanese). Gan to Kagaku Ryoho 16:2563–2576PubMed

35.

Nakazato H, Koike A, Ichihashi H (1989) Results of a randomized controlled trial using adjuvant immunochemotherapy in patients surgically treated for gastric cancer (in Japanese). Biotherapy 3:1356–1360

36.

Sakaguchi Y, Moriguchi S, Maehara Y et al (1989) Effect of postoperative long-term cancer chemotherapy (PLCC) on 15 year survival rate of gastric cancer patients (in Japanese). Biotherapy 3:1353–1355

37.

Hattori T, Nakajima T, Nakazato H et al (1990) Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg 20:127–136PubMedCrossRef

38.

Kondo M (1994) Immunotherapy as adjuvant treatment after curative resection of gastric cancer [comment]. Lancet 344:274PubMedCrossRef

39.

Mitomi T, Ogoshi K (1986) Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer (in Japanese). Gan To Kagaku Ryoho 13:2532–2537PubMed

40.

Saji S, Takao H, Kida H et al (1987) Effects of postoperative adjuvant immunochemotherapy using PSK for patients of gastric cancer, and its preventive effects on the recurrence (in Japanese). Prog Med 7:1703–1709

41.

Maehara Y, Moriguchi S, Sakaguchi Y et al (1990) Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 45:169–172PubMedCrossRef

42.

Maehara Y, Emi Y, Sakaguchi Y et al (1990) Postoperative long-term cancer chemotherapy (PLCC) is effective for patients with gastric cancer following curative resection (in Japanese). Nippon Geka Gakkai Zasshi 9:1368–1370

43.

Maehara Y, Inutsuka S, Takeuchi H, Baba H, Kusumoto H, Sugimachi K (1993) Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer Chemother Pharmacol 33:171–175PubMedCrossRef

44.

Nakao I, Yokoyama T, Urushizaki I et al (1985) Clinical outcome of PSK for advanced gastric cancer (in Japanese). Oncologia 14:163–169

45.

Nakazato H, Ichihashi H, Kondo T (1986) Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer. Cooperative Study Group of Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group (in Japanese). Gan To Kagaku Ryoho 13:308–318PubMed

46.

47.

Nio Y, Tsubono M, Tseng CC et al (1992) Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer (in Japanese). Biotherapy 4:117–128PubMedCrossRef

48.

Takahashi Y, Mai M, Nakazato H (2005) Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU. Anticancer Res 25:1377–1384PubMed

49.

Saji S, Kida T, Kunieda K et al (1985) Five-year survival of gastric cancer patients treated with postoperative long term adjuvant immunochemotherapy. Prog Med 5:485–492

50.

Akimoto M, Nishihira T, Kasai M (1986) Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions (in Japanese). Gan to Kagaku Ryoho 13:1270–1276PubMed

51.

Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M (1997) Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 40:233–238PubMedCrossRef

52.

Hanazaki K, Sodeyama H, Yokoyama S et al (1998) Postoperative chemotherapy may improve prognosis in unresectable gastric cancer. J Clin Gastroenterol 26:269–273PubMedCrossRef

53.

Kuroda Y, Horikawa N, Tsuji M et al (1998) Usefulness of polysaccharide K (PSK) as postoperative adjuvant immunotherapy in patients with stage IV gastric cancer. Int J Clin Oncol 3:311–316

54.

Ogoshi K, Miyaji M, Iwata K, Kondo Y, Tajima T, Mitomi T (1990) Effect of postoperative adjuvant immunochemotherapy on panperitonitis carcimatous stomach cancer (in Japanese). Biotherapy 4:676–679

55.

Sakamoto J, Koike A, Saji S, Teramukai S, Ohashi Y, Nakazato H (1992) Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK. Jpn J Surg 22:530–536CrossRef

56.

Toge T, Yamaguchi Y (2000) Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep 7:1157–1161PubMed

57.

Sakamoto J, Teramukai S, Nakazato H et al (2002) Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother 25:405–412PubMedCrossRef

58.

Algarra I, Collado A, Garrido F (1999) Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones. J Exp Clin Cancer Res 16:373–380

59.

Nio Y, Tsubono M, Tseng CC et al (1992) Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy 4:117–128PubMedCrossRef

60.

Pedrinaci S, Algarra I, Garrido F (1999) Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res 29:135–140PubMedCrossRef

61.

Shibata M, Nezu T, Fujisaki S, Andou K, Tomita R, Fukuzawa M (2002) Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Dig Surg 19:255–260PubMedCrossRef

62.

Ueda Y, Fujimura T, Kinami S et al (2006) A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol [Epub ahead of print]

Titel: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer
verfasst von: Koji Oba
Satoshi Teramukai
Michiya Kobayashi
Takanori Matsui
Yasuhiro Kodera
Junichi Sakamoto
Publikationsdatum: 01.06.2007
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 6/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-006-0248-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

The distinct effects of three tandem repeats of C3d in the immune responses against tumor-associated antigen hCGβ by DNA immunization

Immunization of Rhesus monkeys with a SialylTn–mAb17-1A conjugate vaccine co-formulated with QS-21 induces a temporary systemic cytokine release and NK cytotoxicity against tumor cells

Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins

Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro

In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines

Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie